• biotech job,biopharma variation,Pharmaceutical employees

A recent survey offers a biopharma variation on the sentiment captured memorably if inelegantly a generation ago when Johnny Paycheck sang, "Take This Job and Shove It."

Read more

  • Pharmaceutical,Polls and Research, Health Care & Hospitals, Medical Pharmaceuticals

This report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in US$ Thousand by the following Dosage Forms: Injectables, Solid Dosage Forms , and Liquid & Semi-solid Dosage Forms .

Read more

  • methanol,united states of america, Surveys, Polls and Research, Chemical, Gas

China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors says

Read more

  • Siemens,Cerner,electronic medical,health information technology,$1.3 billion

Cerner Corp. (CERN), an electronic medical records provider, said it would buy Siemens AG (SIE)’s health information technology unit for $1.3 billion.

Read more

  • Allied Minds,Bristol-Myers Squibb,Allied-Bristol Life Sciences LLC

Allied Minds and Bristol-Myers Squibb Company today announced the formation of Allied-Bristol Life Sciences LLC, a new jointly owned enterprise created to identify and foster research and pre-clinical development of biopharmaceutical innovations from leading university research institutions across the U.S.

Read more

  • AstraZeneca,Kyowa Hakko Kirin,immuno-oncology,clinical,partner

AstraZeneca announced that it has entered into a clinical study collaboration with Kyowa Hakko Kirin for a Phase I/Ib immuno-oncology study that will evaluate the safety and efficacy of two separate combinations of three investigational compounds in multiple solid tumours.

Read more

  • AstraZeneca,QIAGEN,cancer,IRESSA,collaboration

AstraZeneca today announced that it has entered into a collaboration with Netherlands-based QIAGEN to develop a non-invasive diagnostic test to identify non-small cell lung cancer (NSCLC) patients who are suitable for treatment with IRESSA?.

Read more

  • Genentech,Roche,Novartis,CIU,Xolair,omalizumab

First Biologic Medicine Approved for CIU, a Burdensome Skin Condition that Can Cause Hives and Severe Itch and May Last Many Years1,2

Read more


Recent News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.